A Phase 3 interventional study of Emapalumab in Primary Hemophagocytic Lymphohistiocytosis, sponsored by Swedish Orphan Biovitrum. Completed at 27 sites in 8 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 3, and was the 26th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–99
Jerry Lee, MD, MSc, MPhil · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–120
University of Alabama at Birmingham · Sites in United States
Electra Therapeutics Inc. · Sites in United States, Austria, Germany and 4 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 6
First in 2000; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is above the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 21 across the 32 interventional studies, 200 across the 9 observational. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 42 have an industry lead sponsor. The 10 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 9 studies filed under Lymphohistiocytosis, Hemophagocytic — fewer than ten, so there is no comparison to draw.
3 of the studies in Lymphohistiocytosis, Hemophagocytic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03827343National Cancer Institute (NCI)Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer | 2026-12-31 |
| NCT05277272Children's Hospital Medical Center, CincinnatiINTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab (previously known as NI-0501) as a treatment for primary haemophagocytic lymphohistiocytosis (HLH) patients, including on long-term outcomes and quality of life assessments. Emapalumab can be administered as the first-line therapy to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the available standard of care.
Emapalumab is to be administered until the start of conditioning for hematopoietic stem cell transplantation (HSCT), with an anticipated duration ranging from a minimum of 4 weeks to approximately 12 weeks and not exceeding 6 months.
After treatment completion, patients will continue in the study for long-term follow-up until 1 year after either HSCT or last emapalumab infusion (if HSCT is not performed).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Emapalumab
Emapalumab will be administered by intravenous infusion, twice weekly.
Overall Response at Week 8 or End of Treatment (if Earlier)
The overall response rate (ORR) of patients achieving either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier).
Time frame: Up to Week 8
Overall Survival at End of Study
Number of patients surviving to the end of the study.
Time frame: Up to 18 months
Overall Survival to HSCT
Number of patients surviving to HSCT.
Time frame: From start of treatment to HSCT or from start of treatment until 1 year after EOT for patient who did not undergo HSCT
Overall Survival for Patients Receiving HSCT
Number of patients surviving post HSCT.
Time frame: Up to 1 year post HSCT
Event-free Survival
Number of patients experiencing event-free survival, the duration of which was defined as time from HSCT to date of (whichever occurs first): death from any cause, graft failure, or HLH reactivation.
Time frame: Up to 1 year post HSCT
Overall Response at Start of Conditioning
Number of patients achieving either a Complete or Partial Response or HLH Improvement, at start of conditioning (or at last emapalumab infusion if HSCT is not performed).
Time frame: Up to 6 months
Duration of Response
Duration of response, i.e., maintenance of the response achieved at any time during the study (with censoring time at start of conditioning for patients with no event) calculated only for patients showing confirmed overall response. Summarized by number of patients experiencing each category of response duration.
Time frame: Up to 18 months
Time to Response
Time to first response at any time during the study.
Time frame: Up to 18 months
Number of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment
Number of patients able to reduce glucocorticoids by 50% or more of the baseline dose during emapalumab treatment.
Time frame: Up to 6 months
Number of Patients Proceeding to HSCT
Number of patients able to proceed to HSCT when deemed indicated.
Time frame: Up to 18 months
Quality of Life Assessed Through PedsQL™, Pediatric Quality of Life Inventory™
Assessment of the quality of life using the PedsQL "Pediatric Quality of Life Inventory". The PedsQL uses a 100-point scale ranging from 0 to 100 with higher values indicating better quality of life.
Time frame: Up to 6 months
Quality of Life Assessed Through Behavioral, Affective and Somatic Experiences Scales (BASES)
Assessment of the quality of life using the BASES questionnaire, which is a validated 38-item questionnaire; a reduced nonvalidated 22-item version of the questionnaire is used in an exploratory nature for the secondary endpoint. Subscale scores were calculated using a 5-point Likert scale from 1 to 5 for all questions. Scores for all questions in each subscale were added up and divided by the number of patients in the analysis population to reach the mean score. Subscale scores were calculated for the following domains: * Physical Discomfort (5 questions, '1' = best response, total range 5-25) * Cooperation/Compliance (5 questions, '1' = best response, total range 5-25) * Mood/Behavior (7 questions, '5' = best response, total range 7-35) * Quality of Interactions (3 questions, '1' = best response, total range 3-15) * Activity/Sleep (2 questions, '5' = best response for patient's activity level and '1' = best response for patient's sleeping, total range 2-10)
Time frame: Up to 6 months
Incidence, Severity, Causality and Outcomes of AEs (Serious and Non-serious)
Incidence of adverse events. SAE = serious adverse event; TEAE = treatment-emergent adverse event
Time frame: Up to 18 months
Evolution of Laboratory Parameters Change From Baseline to EOT/Week 8
Number of patients experiencing shifts from baseline in the following relevant laboratory parameters are reported: * Biochemistry: glucose ferritin, C-reactive protein (CRP), liver function (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma glutamyl transferase \[γGT\], lactate dehydrogenase \[LDH\], bilirubin, renal function (albumin, creatinine, urea, urea nitrogen), triglycerides * Complete blood count: basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, large unstained cells, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils band form, neutrophils band form/leukocytes, platelets, erythrocytes, leukocytes * Coagulation tests (activated partial thromboplastin time \[aPTT\], aPTT ratio, prothrombin time, prothrombin international normalized ratio \[INR\]), D-dimer, fibrinogen
Time frame: To Week 8 or End of treatment if before Week 8.
Number of Patients Who Discontinued Emapalumab Treatment
Number of patients who discontinued emapalumab treatment for safety reasons.
Time frame: Up to 6 months
Serum Concentrations of Emapalumab
The serum concentration of emapalumab will be measured as a function of time to determine the emapalumab PK profile.
Time frame: Up to Week 8, with data presented at Baseline and EOT/W8
Change in Pharmacodynamic Parameters
Levels (in ng/L) of total IFNγ (interferon gamma), markers of its neutralization (CXCL9 and CXCL10), and sCD25.
Time frame: Up to 18 months with data presented at Baseline and EOT/W8
Number of Patients Who Demonstrated a Presence of Circulating Antibodies Against Emapalumab to Determine Immunogenicity
The presence of circulating antibodies against emapalumab was inferred by positive results for anti-drug antibodies (ADAs).
Time frame: Up to 1 year follow up post end of treatment with assessments at first dose of emapalumab, Week 4, Week 8, EOT and following treatment at day 100 and at the 1 year follow up visit, with data presented at study day 21 and EOT/Week 8.
| Milestone | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|
| Started | 16 | 19 |
| Completed | 9 | 9 |
| Not completed | 7 | 10 |
| Withdrew: Death | 7 | 9 |
| Withdrew: Study discontinuation due to other reason | 0 | 1 |
The overall response rate (ORR) of patients achieving either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier).
| Percentage of participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Overall Response at Week 8 or End of Treatment (if Earlier) | 62.9 (44.9 to 78.5) | 50.0 (24.7 to 75.3) | 73.7 (48.8 to 90.9) |
Number of patients surviving to the end of the study.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Alive at end of study | 19 | 9 | 10 |
| Early discontinuation | 1 | 0 | 1 |
Number of patients surviving to HSCT.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Overall Survival to HSCT | 25 | 12 | 13 |
Number of patients surviving post HSCT.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Overall Survival for Patients Receiving HSCT | 17 | 8 | 9 |
Number of patients experiencing event-free survival, the duration of which was defined as time from HSCT to date of (whichever occurs first): death from any cause, graft failure, or HLH reactivation.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Event-free Survival | 16 | 8 | 8 |
Number of patients achieving either a Complete or Partial Response or HLH Improvement, at start of conditioning (or at last emapalumab infusion if HSCT is not performed).
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Complete response | 4 | 3 | 1 |
| Partial response | 11 | 5 | 6 |
| HLH improvement | 1 | 0 | 1 |
| No response | 19 | 8 | 11 |
Duration of response, i.e., maintenance of the response achieved at any time during the study (with censoring time at start of conditioning for patients with no event) calculated only for patients showing confirmed overall response. Summarized by number of patients experiencing each category of response duration.
| days | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Duration of Response | 61 (29.0 to NA) | 40 (19.0 to NA) | 61 (21.0 to NA) |
Time to first response at any time during the study.
| days | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Time to Response | 4 (4.0 to 13.0) | 5 (4.0 to 21.0) | 4 (4.0 to 30.0) |
Number of patients able to reduce glucocorticoids by 50% or more of the baseline dose during emapalumab treatment.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Number of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment | 15 | 8 | 7 |
Number of patients able to proceed to HSCT when deemed indicated.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Number of Patients Proceeding to HSCT | 23 | 11 | 12 |
Assessment of the quality of life using the PedsQL "Pediatric Quality of Life Inventory". The PedsQL uses a 100-point scale ranging from 0 to 100 with higher values indicating better quality of life.
| scale on a score | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Change from Baseline at EOT/Week 8 - 1-12 months | 0.208 ± 18.0737 | -6.514 ± 14.8977 | 5.810 ± 19.8220 |
| Change from Baseline at EOT/Week 8 - 13-24 months | 0.794 ± 4.8152 | — | 0.794 ± 4.8152 |
| Change from Baseline at EOT/Week 8 - 2-4 years | 8.469 ± 9.6897 | — | 8.469 ± 9.6897 |
| Change from Baseline at EOT/Week 8 - 8-12 years | 15.978 | 15.978 | — |
| Change from Baseline at EOT/Week 8 - 13-18 years | -7.862 ± 13.4760 | — | -7.862 ± 13.4760 |
Assessment of the quality of life using the BASES questionnaire, which is a validated 38-item questionnaire; a reduced nonvalidated 22-item version of the questionnaire is used in an exploratory nature for the secondary endpoint. Subscale scores were calculated using a 5-point Likert scale from 1 to 5 for all questions. Scores for all questions in each subscale were added up and divided by the number of patients in the analysis population to reach the mean score. Subscale scores were calculated for the following domains: * Physical Discomfort (5 questions, '1' = best response, total range 5-25) * Cooperation/Compliance (5 questions, '1' = best response, total range 5-25) * Mood/Behavior (7 questions, '5' = best response, total range 7-35) * Quality of Interactions (3 questions, '1' = best response, total range 3-15) * Activity/Sleep (2 questions, '5' = best response for patient's activity level and '1' = best response for patient's sleeping, total range 2-10)
| scale on a score | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Physical discomfort | 10.0 ± 3.57 | 9.4 ± 2.99 | 10.5 ± 4.14 |
| Cooperation/compliance | 9.3 ± 3.02 | 9.6 ± 2.76 | 9.1 ± 3.4 |
| Mood/behavior | 20.4 ± 8.82 | 15.1 ± 8.88 | 25.0 ± 6.02 |
| Quality of interactions | 5.8 ± 2.34 | 6.1 ± 2.48 | 5.5 ± 2.33 |
| Activity | 3.1 ± 1.22 | 2.7 ± 0.95 | 3.4 ± 1.41 |
| Sleep | 2.1 ± 1.04 | 1.8 ± 1.10 | 2.3 ± 1.03 |
Incidence of adverse events. SAE = serious adverse event; TEAE = treatment-emergent adverse event
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Non-TEAEs | 15 | 5 | 10 |
| TEAEs | 35 | 16 | 19 |
| TEAEs related to study drug | 9 | 3 | 6 |
| Mild TEAEs | 30 | 12 | 18 |
| Moderate TEAEs | 27 | 12 | 15 |
| Severe TEAEs | 31 | 15 | 16 |
| TEAEs leading to discontinuation of study drug | 7 | 3 | 4 |
| TEAEs with an outcome of death | 16 | 7 | 9 |
| Serious TEAEs | 32 | 16 | 16 |
| Treatment-emergent SAEs related to study drug | 4 | 2 | 2 |
| TEAEs with infections | 29 | 14 | 15 |
| Mild infections | 21 | 10 | 11 |
| Moderate infections | 15 | 8 | 7 |
| Severe infections | 16 | 7 | 9 |
| TEAEs with infusion-related reactions | 7 | 3 | 4 |
Number of patients experiencing shifts from baseline in the following relevant laboratory parameters are reported: * Biochemistry: glucose ferritin, C-reactive protein (CRP), liver function (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma glutamyl transferase \[γGT\], lactate dehydrogenase \[LDH\], bilirubin, renal function (albumin, creatinine, urea, urea nitrogen), triglycerides * Complete blood count: basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, large unstained cells, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils band form, neutrophils band form/leukocytes, platelets, erythrocytes, leukocytes * Coagulation tests (activated partial thromboplastin time \[aPTT\], aPTT ratio, prothrombin time, prothrombin international normalized ratio \[INR\]), D-dimer, fibrinogen
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Albumin: low to within | 6 | 3 | 3 |
| Albumin: within to low | 2 | 0 | 2 |
| Alkaline phosphatase: low to within | 5 | 1 | 4 |
| Alkaline phosphatase: within to low | 8 | 5 | 3 |
| Alkaline phosphatase: high to within | 2 | 1 | 1 |
| Alanine aminotransferase: within to high | 3 | 1 | 2 |
| Alanine aminotransferase: high to within | 8 | 6 | 2 |
| Aspartate aminotransferase: within to high | 3 | 0 | 3 |
| Aspartate aminotransferase: high to low | 1 | 1 | 0 |
| Aspartate aminotransferase: high to within | 8 | 5 | 3 |
| Bilirubin: within to low | 1 | 1 | 0 |
| Bilirubin: within to high | 1 | 0 | 1 |
| Bilirubin: high to within | 4 | 2 | 2 |
| Creatinine: low to within | 1 | 0 | 1 |
| Creatinine: within to low | 5 | 1 | 4 |
| Creatinine: within to high | 1 | 0 | 1 |
| Creatinine: high to within | 2 | 1 | 1 |
| C-reactive protein: within to high | 6 | 2 | 4 |
| C-reactive protein: high to within | 4 | 1 | 3 |
| Ferritin: high to low | 1 | 1 | 0 |
| Ferritin: high to within | 5 | 3 | 2 |
| γGT: within to high | 3 | 1 | 2 |
| γGT: high to within | 4 | 3 | 1 |
| Glucose: within to high | 2 | 2 | 0 |
| Glucose: high to within | 8 | 4 | 4 |
| Lactate dehydrogenase: low to within | 1 | 0 | 1 |
| Lactate dehydrogenase: within to high | 4 | 2 | 2 |
| Lactate dehydrogenase: high to within | 8 | 5 | 3 |
| Triglycerides: within to high | 1 | 0 | 1 |
| Triglycerides: high to within | 5 | 3 | 2 |
| Urea: within to low | 5 | 2 | 3 |
| Urea: within to high | 4 | 2 | 2 |
| Urea: high to within | 4 | 1 | 3 |
| Urea nitrogen: low to within | 1 | 1 | 0 |
| Urea nitrogen: within to low | 1 | 1 | 0 |
| Urea nitrogen: within to high | 1 | 1 | 0 |
| Basophils: low to within | 1 | 0 | 1 |
| Basophils: within to high | 1 | 0 | 1 |
| Basophils: high to within | 1 | 1 | 0 |
| Basophils/leukocytes: high to within | 1 | 1 | 0 |
| Eosinophils: low to within | 3 | 1 | 2 |
| Eosinophils: within to low | 1 | 1 | 0 |
| Eosinophils/leukocytes: within to high | 2 | 1 | 1 |
| Hematocrit: low to within | 9 | 4 | 5 |
| Hematocrit: within to low | 5 | 2 | 3 |
| Hemoglobin: low to within | 9 | 5 | 4 |
| Hemoglobin: low to high | 1 | 0 | 1 |
| Hemoglobin: within to low | 5 | 1 | 4 |
| Large unstained cells: high to within | 1 | 1 | 0 |
| Lymphocytes: low to within | 4 | 2 | 2 |
| Lymphocytes: within to low | 6 | 3 | 3 |
| Lymphocytes: within to high | 1 | 1 | 0 |
| Lymphocytes: high to within | 1 | 1 | 0 |
| Lymphocytes/leukocytes: within to high | 1 | 1 | 0 |
| Lymphocytes/leukocytes: within to low | 4 | 2 | 2 |
| Lymphocytes/leukocytes: high to within | 2 | 2 | 0 |
| Monocytes: low to within | 6 | 2 | 4 |
| Monocytes: low to high | 3 | 0 | 3 |
| Monocytes: within to low | 2 | 1 | 1 |
| Monocytes: within to high | 2 | 2 | 0 |
| Monocytes: high to within | 2 | 0 | 2 |
| Monocytes/leukocytes: within to high | 3 | 3 | 0 |
| Monocytes/leukocytes: high to within | 1 | 1 | 0 |
| Neutrophils band form: low to within | 9 | 3 | 6 |
| Neutrophils band form: within to low | 2 | 1 | 1 |
| Neutrophils band form: within to high | 2 | 0 | 2 |
| Neutrophils band form: high to within | 1 | 1 | 0 |
| Neutrophils band form/leukocytes: low to within | 2 | 1 | 1 |
| Neutrophils band form/leukocytes: within to low | 1 | 1 | 0 |
| Neutrophils band form/leukocytes: within to high | 1 | 1 | 0 |
| Platelets: low to within | 5 | 2 | 3 |
| Platelets: low to high | 2 | 2 | 0 |
| Platelets: within to low | 3 | 1 | 2 |
| Platelets: within to high | 1 | 0 | 1 |
| Platelets: high to within | 1 | 0 | 1 |
| Erythrocytes: low to within | 8 | 4 | 4 |
| Erythrocytes: within to low | 4 | 2 | 2 |
| Erythrocytes: within to high | 1 | 0 | 1 |
| Leukocytes: low to within | 9 | 2 | 7 |
| Leukocytes: low to high | 1 | 1 | 0 |
| Leukocytes: within to low | 4 | 3 | 1 |
| Leukocytes: high to within | 1 | 1 | 0 |
| aPTT: low to within | 2 | 1 | 1 |
| aPTT: within to low | 4 | 2 | 2 |
| aPTT: within to high | 3 | 1 | 2 |
| aPTT: high to within | 4 | 3 | 1 |
| aPTT ratio: low to within | 2 | 0 | 2 |
| aPTT ratio: within to low | 1 | 0 | 1 |
| aPTT ratio: within to high | 2 | 0 | 2 |
| aPTT ratio: high to within | 2 | 2 | 0 |
| D-dimer: within to high | 4 | 0 | 4 |
| D-dimer: high to within | 6 | 4 | 2 |
| Fibrinogen: low to within | 13 | 6 | 7 |
| Fibrinogen: low to high | 1 | 0 | 1 |
| Fibrinogen: within to low | 2 | 1 | 1 |
| Fibrinogen: within to high | 2 | 1 | 1 |
| Fibrinogen: high to within | 3 | 1 | 2 |
| Prothrombin time: within to high | 3 | 1 | 2 |
| Prothrombin time: high to within | 6 | 3 | 3 |
| Prothrombin INR: within to high | 1 | 0 | 1 |
| Prothrombin INR: high to low | 1 | 1 | 0 |
| Prothrombin INR: high to within | 4 | 2 | 2 |
Number of patients who discontinued emapalumab treatment for safety reasons.
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Number of Patients Who Discontinued Emapalumab Treatment | 7 | 3 | 4 |
The serum concentration of emapalumab will be measured as a function of time to determine the emapalumab PK profile.
| ng/mL | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Emapalumab serum concentration at Baseline pre-dose | 14.311 ± 50.2717 | 12.899 ± 49.9589 | 15.425 ± 51.8562 |
| Emapalumab serum concentration at EOT/Week 8 pre-dose | 258337.456 ± 231412.7632 | 295521.381 ± 296009.6195 | 231482.400 ± 175589.7297 |
| Emapalumab serum concentration at EOT/Week 8 post-dose | 142338.620 ± 89464.1682 | 205599.340 ± NA | 79077.900 ± NA |
Levels (in ng/L) of total IFNγ (interferon gamma), markers of its neutralization (CXCL9 and CXCL10), and sCD25.
| ng/L | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Total IFNγ at baseline | 1112.681 ± 2393.9753 | 1356.191 ± 2550.8868 | 920.436 ± 2314.6502 |
| Total IFNγ at EOT/Week 8 | 25708.836 ± 41775.8890 | 39233.258 ± 60957.7563 | 15941.198 ± 14695.7764 |
| CXCL10 at baseline | 14195.394 ± 37588.5073 | 28501.304 ± 54928.0152 | 3654.197 ± 7505.8959 |
| CXCL10 at EOT/Week 8 | 3203.194 ± 13239.6238 | 6355.428 ± 20287.7247 | 926.580 ± 2389.4231 |
| CXCL9 at baseline | 14113.999 ± 34451.6041 | 26695.379 ± 49400.5090 | 4181.331 ± 6470.0963 |
| CXCL9 at EOT/Week 8 | 2109.078 ± 10100.8802 | 4749.055 ± 15555.8338 | 202.428 ± 240.9550 |
| sCD25 at baseline | 17026.171 ± 13537.8951 | 23980.603 ± 13267.5834 | 11535.830 ± 11268.1072 |
| sCD25 at EOT/Week 8 | 9882.585 ± 8542.0418 | 11301.162 ± 8847.8000 | 8858.058 ± 8417.5485 |
The presence of circulating antibodies against emapalumab was inferred by positive results for anti-drug antibodies (ADAs).
| Participants | All-treated Analysis Set | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced |
|---|---|---|---|
| Presence of circulating antibodies at Study Day 21 | 2 | 2 | 0 |
| Presence of circulating antibodies at End of Treatment/Week 8 | 1 | 0 | 1 |
Collected over Signing of ICF until end of long-term follow-up (1 year after either HSCT or the last emapalumab infusion if HSCT was not performed). Through study completion. The average time 285 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All-treated Analysis Set - Treatment naïve | 7/16 (43.8%) | 16/16 (100%) | 14/16 (87.5%) |
| All-treated Analysis Set - Treatment Experienced | 9/19 (47.4%) | 16/19 (84.2%) | 19/19 (100%) |
| All-treated Analysis Set | 16/35 (45.7%) | 32/35 (91.4%) | 35/35 (100%) |
| Event | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | All-treated Analysis Set |
|---|---|---|---|
| Condition aggravatedGeneral disorders | 4/16 | 8/19 | 12/35 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/16 | 4/19 | 5/35 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/16 | 0/19 | 3/35 |
| PyrexiaGeneral disorders | 2/16 | 3/19 | 5/35 |
| SeizureNervous system disorders | 0/16 | 3/19 | 3/35 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/16 | 3/19 | 4/35 |
| Staphylococcal sepsisInfections and infestations | 2/16 | 1/19 | 3/35 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/16 | 2/19 | 4/35 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/16 | 2/19 | 4/35 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/16 | 0/19 | 2/35 |
| Event | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | All-treated Analysis Set |
|---|---|---|---|
| VomitingGastrointestinal disorders | 7/16 | 10/19 | 17/35 |
| DiarrhoeaGastrointestinal disorders | 5/16 | 10/19 | 15/35 |
| PyrexiaGeneral disorders | 6/16 | 8/19 | 14/35 |
| HypertensionVascular disorders | 6/16 | 5/19 | 11/35 |
| PainGeneral disorders | 3/16 | 6/19 | 9/35 |
| Abdominal painGastrointestinal disorders | 2/16 | 5/19 | 7/35 |
| RashSkin and subcutaneous tissue disorders | 4/16 | 4/19 | 8/35 |
| StomatitisGastrointestinal disorders | 2/16 | 4/19 | 6/35 |
| Mucosal inflammationGeneral disorders | 1/16 | 4/19 | 5/35 |
| PruritusSkin and subcutaneous tissue disorders | 1/16 | 4/19 | 5/35 |
| Age, Categorical(Participants) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| <=18 years | 16 | 19 | 35 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| Female | 3 | 11 | 14 |
| Male | 13 | 8 | 21 |
| Ethnicity (NIH/OMB)(Participants) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 3 |
| Not Hispanic or Latino | 12 | 18 | 30 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 3 | 1 | 4 |
| White | 6 | 12 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 5 | 7 |
| Body Weight (kg)(kg) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| Mean | 9.599 ± 10.5915 | 13.946 ± 14.4351 | 11.959 ± 12.8309 |
| Height/Length (cm)(cm) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| Mean | 67.02 ± 27.416 | 83.41 ± 37.790 | 75.96 ± 34.003 |
| Body Surface Area (m^2)(m^2) | All-treated Analysis Set - Treatment naïve | All-treated Analysis Set - Treatment Experienced | Total |
|---|---|---|---|
| Mean | 0.415 ± 0.3022 | 0.564 ± 0.4141 | 0.497 ± 0.3698 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2019 to primary completion in Aug 2021, 30 months.
Results were first posted in Mar 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emapalumab
Lymphohistiocytosis, Hemophagocytic →